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Abstract
Glioma is a deadly brain cancer, and current treatments have been
unsuccessful in prolonging life more than a few months. In an effort to
discover better treatments with more direct targets, we are conducting a
chemical screen using Tyrosine Kinase inhibitors (Selleck Biochem).
Promising results of such inhibitors will suppress the progression of
glioma by (a) inhibiting the underlying molecular pathways activated in
glioma, or (b) prevent rapid proliferation of the glia and other cells that
encompass the glioma tumor. We have induced glioma in Drosophila by
activating two of the most common oncogenic pathways, PI3K and
Ras/MAPK. The activation of these pathways results in an enlarged
brain from an increase in stem cells and their glia and neural progeny.
These tumors cause the larvae to enter a prolonged larval phase, and
eventually kill the organism. During our screen, larvae are added to food
in their early third instar phase (72h old). The food is infused with 10 or
300uM chemicals in DMSO and where we then see effects on glioma
growth, and survival in mature third instar stage (120h old). Using these
metrics, here we present data from our screen on promising drugs from
this academic year’s testing focusing on drugs E7, E9, and E11. Once
we identify potential glioma inhibitors in the primary screens, we will
validate them in secondary screens.

Introduction
The goal of this experiment is to determine the limit of growth and
progression of glioma after being treated with recently approved drugs that
target Tyrosine kinases. The pathway used for the limit of the growth and
progression of glioma are the Ras/MAPK and PI3K pathways in the model
organism, Drosophila Melanogaster. The most frequent oncogenic
mutation in most tumors, along with glioma is RasV12. When RasV12 is
activated, the result is cell proliferation and tumor invasions.

Table 1: Drug Data Summary
10um

300um

E7 Drugs

In Progress.

Showed slight Reduction.

E9 Drugs

No visual change
in glioma size

In Progress.

E11 Drugs

Showed overall
suppression

In Progress.

P1E11 (10um) – Suppression

Conclusions

Scales Used for Comparison
Control

Smaller

Larger

•

•

•
•
•

Repo>GFP

Repo>GFP;
Pteni; RasV12

P1E9 (10um) – No Change

P1E7 (300um) - Suppression

The PI3K pathway, a growth regulatory pathway that’s responsive to
growth factors, is also known to be responsive to many tumor suppressor
genes apart of the same pathway. Pten is one of those tumor suppressor
genes and it results in negative regulation of the PI3K pathway. We
expressed PtenRNAi with activated RasV12 to successfully model glioma in
fly brains, since Pten mutations are found in patients’ biopsies of glioma.
In this chemical screen, we tested the effectiveness of chemicals, more
specifically the effectiveness of chemicals E7, E8, E11. The effectiveness
is examined by dissecting the brain, along with imaging larvae brains and
checking the survival rates of the larvae. We present our results on the
inhibitors effect on glioma growth and the evidence for the overall
effectiveness of this screen on the model organism.
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The present drug screen examined potential tumor suppressing
effects of tyrosine kinase inhibitors from a chemical library tested in a
Drosophila model of glioma.
Through our drug screen, we have tested drugs A-H in the chemical
library. We have focused the present poster on P1E7, P1E9, and
P1E11. Through our current results, we found that chemicals P1E7
and P1E11 both had tumor suppressing effects, at 300 uM and 10
uM respectively.
The chemical P1E9 demonstrated no change in glioma size.
Since both P1E7 and P1E11 demonstrated glioma inhibition, we plan
to further validate these findings by performing secondary screens.
In the future, we will continue analyzing other drugs from the
chemical library in order to determine which chemicals are most
effective in inhibiting glioma growth, as well as their optimal
concentrations.

Future Directions
1. We plan to continue the chemical screen using additional drugs
from the Selleck Biochem Chemical library.
2. We will begin to validate the potential glioma reducers to find the
specificity and efficacy of these potential modifiers of glioma
growth.
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